Kiniksa Pharmaceuticals, Ltd.

NasdaqGS KNSA

Kiniksa Pharmaceuticals, Ltd. Free Cash Flow Yield on December 30, 2024: 0.78%

Kiniksa Pharmaceuticals, Ltd. Free Cash Flow Yield is 0.78% on December 30, 2024, a -21.97% change year over year. Free cash flow yield compares the return from free cash flow to the market cap; higher yield suggests attractive investment.
  • Kiniksa Pharmaceuticals, Ltd. 52-week high Free Cash Flow Yield is 2.37% on July 01, 2024, which is 201.66% above the current Free Cash Flow Yield.
  • Kiniksa Pharmaceuticals, Ltd. 52-week low Free Cash Flow Yield is 0.56% on October 28, 2024, which is -29.04% below the current Free Cash Flow Yield.
  • Kiniksa Pharmaceuticals, Ltd. average Free Cash Flow Yield for the last 52 weeks is 1.26%.
Key data
Date Free Cash Flow Yield Market Value Added (MVA) Price to Book Ratio (P/B) Price to Earnings Ratio (P/E)
Market news
Loading...
NasdaqGS: KNSA

Kiniksa Pharmaceuticals, Ltd.

CEO Mr. Sanj K. Patel
IPO Date May 25, 2018
Location Bermuda
Headquarters Clarendon House
Employees 297
Sector Health Care
Industries
Description

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.

Similar companies

CHRS

Coherus BioSciences, Inc.

USD 1.44

-2.04%

ACLX

Arcellx, Inc.

USD 64.65

-4.02%

LRMR

Larimar Therapeutics, Inc.

USD 3.29

-5.46%

VTYX

Ventyx Biosciences, Inc.

USD 1.94

-0.51%

KURA

Kura Oncology, Inc.

USD 7.26

0.28%

NVCT

Nuvectis Pharma, Inc.

USD 5.64

-2.93%

PHAT

Phathom Pharmaceuticals, Inc.

USD 6.79

2.57%

DAWN

Day One Biopharmaceuticals, Inc.

USD 11.16

-3.46%

CGEM

Cullinan Oncology, Inc.

USD 10.01

-9.33%

GPCR

Structure Therapeutics Inc.

USD 25.38

0.87%

COGT

Cogent Biosciences, Inc.

USD 7.37

-2.64%

REPL

Replimune Group, Inc.

USD 10.49

-3.67%

NUVL

Nuvalent, Inc.

USD 72.39

0.74%

StockViz Staff

January 15, 2025

Any question? Send us an email